MedPath

Effects of RIC on Cognitive Function and Blood Oxygen Levels in Unacclimatized Adult at High Altitude

Not Applicable
Conditions
Adult
Interventions
Device: RIC
Device: sham RIC
Registration Number
NCT03728114
Lead Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Brief Summary

Several studies have shown cognitive impairment such as memory, perception and learning skill during ascent to high altitudes. However, few studies have directly investigated the effect of high altitudes exposure on attention-a high-level cognitive function. Remote ischemic conditioning (RIC) is a noninvasive and easy-to-use neuroprotective strategy, It has been proven to be an effective strategy for neuroprotection in ischemic stroke and chronic cerebral ischemia patients.

Detailed Description

This study will provide insights into the preliminary proof of principle, safety, cognitive dysfunction and blood oxygen levels protective effects of RIC in Adults Exposing to High Altitude Conditions, and this data will provide parameters for future larger scale clinical trials if efficacious.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
120
Inclusion Criteria
  • The age was between 19 and 30 years.
  • All participants should meet the criteria which included right-hand dominance, normal or corrected-to-normal vision.
  • the RIC group volunteers have no history of intravascular thrombosis in the bilateral upper limbs;
  • The high altitude participants move into the high-altitude environment within one month, and the low altitude volunteers have long-term life in low altitude areas.
Exclusion Criteria
  • Severe hepatic or renal dysfunction
  • Severe hemostatic disorder or severe coagulation dysfunction
  • Any of the following cardiac disease - rheumatic mitral and or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, patent foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular condition interfering with participation
  • Serious, advanced, or terminal illnesses with anticipated life expectancy of less than one year
  • Patient participating in a study involving other drug or device trial study 7. Patients with existing neurological or psychiatric disease that would confound the neurological or functional evaluations 8. Unlikely to be available for follow-up for 3 months 9. Contraindication for RIC - severe soft-tissue injury, fracture, or peripheral vascular disease in the upper limbs.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High Altitude RIC groupRICThirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
Low Altitude Sham groupsham RICThirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
High Altitude Sham groupsham RICThirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
Low Altitude RIC groupRICThirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
Primary Outcome Measures
NameTimeMethod
Attentional network testchange from baseline (pre-RIC treatment) at 7days after RIC treatment

The computer software attentional network test (ANT) as described by Fan et al. in 2002 will be used to measuring the Orienting function, executive function and alerting function.

Secondary Outcome Measures
NameTimeMethod
The peak systolic blood flow velocity (PSV) of bilateral middle cerebral artery (MCA)change from baseline(pre-RIC treatment) at 7days after RIC treatment

This is a indicator of hemodynamic data ,it is measured by Transcranial Doppler ((DWL Doppler-Box, German) according to applicational specifications and technical standards

end-diastolic blood flow velocity (EDV) of bilateral middle cerebral artery (MCA)change from baseline(pre-RIC treatment) at 7days after RIC treatment

This is a indicator of hemodynamic data ,it is measured by Transcranial Doppler ((DWL Doppler-Box, German) according to applicational specifications and technical standards

the number of patients with any other adverse events related to RIC intervention as determined by the principle investigatorwithin 7 days after RIC treatment

it is an aspect which can reflect the safety of remote ischemic conditioning

basic fibroblast growth factorchange from baseline (pre-RIC treatment) at 7 days after RIC treatment

basic fibroblast growth factor will be detected. Blood samples will be drawn from cubital vein to test these biomarkers.

heart ratechange from baseline(pre-RIC treatment) at 7days after RIC treatment

the heart rate will be measured by automatic blood pressure monitor

blood oxygen saturation (SaO2)change from baseline(pre-RIC treatment) at 7days after RIC treatment

The portable oxygen saturation ward apparatus (Datex -Ohmeda, USA) will be used to monitor the blood oxygen saturation (SaO2)

platelet derived growth factorchange from baseline (pre-RIC treatment) at 7 days after RIC treatment

platelet derived growth facto will be detected. Blood samples will be drawn from cubital vein to test these biomarkers.

the rate of Adverse eventchange from baseline (pre-RIC treatment) at 7 days after RIC treatment

Any adverse event will be reported and its relationship with the RIC intervention will be evaluated.

distal radial pulseswithin 7 days after RIC treatment

It is an aspect which can reflect the safety of remote ischemic conditioning

the number of patients not tolerating RIC procedure,and refuse to continue the RIC procedurewithin 7 days after RIC treatment

it is an aspect which can reflect the safety of remote ischemic conditioning

blood pressurechange from baseline(pre-RIC treatment) at 7days after RIC treatment

Both systolic, and diastolic pressure will be measured by automatic blood pressure monitor

the mean flow velocity (MFV) of the subjects' bilateral middle cerebral artery (MCA)change from baseline (pre-RIC treatment) at 7 days after RIC treatment

This is a indicator of hemodynamic data ,it is measured by Transcranial Doppler ((DWL Doppler-Box, German) according to applicational specifications and technical standards

The degree of palpation of tenderness--visual analogue scalewithin 7 days after RIC treatment

The degree of palpation of tenderness is an aspect which can reflect the safety of remote ischemic conditioning. The pain was assessed with visual analogue scale ( VAS)

the number of patients with any other adverse events related to RIC intervention as determined by the principle investigator.within 7 days after RIC treatment

it is an aspect which can reflect the safety of remote ischemic conditioning

pulse index (PI) of the subjects' bilateral middle cerebral artery (MCA)change from baseline (pre-RIC treatment) at 7 days after RIC treatment

This is a indicator of hemodynamic data ,it is measured by Transcranial Doppler ((DWL Doppler-Box, German) according to applicational specifications and technical standards

vascular endothelial growth factorchange from baseline (pre-RIC treatment) at 7 days after RIC treatment

vascular endothelial growth factor will be detected. Blood samples will be drawn from cubital vein to test these biomarkers.

the number of erythema in the skinwithin 7 days after RIC treatment

It is an aspect which can reflect the safety of remote ischemic conditioning

cerebral oxygen saturation(TOI)change from baseline(pre-RIC treatment) at 7days after RIC treatment

The cerebral oxygen monitor (EGOS-600, Jiangsu China) will be used to monitor the cerebral oxygen saturation (TOI).

© Copyright 2025. All Rights Reserved by MedPath